Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC - NanoViricides, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: donpat who wrote (9506)	12/22/2017 11:42:19 AM
From: donpat	Respond to of 12873

Heparan sulfate and Sialic acid attachment points on cells: goo.gl Abstract Herpes simplex virus type-1 (HSV-1) and type-2 (HSV-2) are highly prevalent human pathogens causing life-long infections. The process of infection begins when the virions bind heparan sulfate moieties present on host cell surfaces. ncbi.nlm.nih.gov

To: donpat who wrote (9506)	12/27/2017 9:29:21 AM
From: donpat	Read Replies (1) \| Respond to of 12873

Our findings demonstrate that it is possible for a single small molecule to inhibit the binding of viruses that depend on heparan sulfate or on sialic acid for attachment, which opens the possibility to develop truly broad-spectrum antivirals targeting primary attachment. A Small Molecule Inhibits Virion Attachment to Heparan Sulfate- or Sialic Acid-Containing Glycans Che C. Colpittsb,c and Luis M. Schanga,b,c L. Hutt-Fletcher, Editor aDepartment of Biochemistry, University of Alberta, Edmonton, AB, Canada bLi Ka Shing Institute of Virology, University of Alberta, Edmonton, AB, Canada cDepartment of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB, Canada Corresponding author. Address correspondence to Luis M. Schang, ac.atreblau@gnahcs.siul. Author information Article notes Copyright and License information ncbi.nlm.nih.gov Broad spectrum! Just what I have been looking for all these years!!!! BroadSpectrumCides - about to go IPO!!!!? Epigallocatechin gallate (EGCG), a green tea catechin, is active against many unrelated viruses, including several that bind to heparan sulfate or to sialic acid. We sought to identify the basis for the broad-spectrum activity of EGCG. Here, we show that EGCG inhibits the infectivity of a diverse group of enveloped and nonenveloped human viruses. EGCG acts directly on the virions, without affecting the fluidity or integrity of the virion envelopes. Instead, EGCG interacts with virion surface proteins to inhibit the attachment of HSV-1, HCV, IAV, vaccinia virus, adenovirus, reovirus, and vesicular stomatitis virus (VSV) virions. We further show that EGCG competes with heparan sulfate for binding of HSV-1 and HCV virions and with sialic acid for binding of IAV virions. Therefore, EGCG inhibits unrelated viruses by a common mechanism. Most importantly, we have identified EGCG as the first broad-spectrum attachment inhibitor. Our results open the possibility for the development of small molecule broad-spectrum antivirals targeting virion attachment. Ref: en.m.wikipedia.org